Chronicle Bio builds AI platform to match drugs to patients by biology

Fidji Simo, OpenAI's CEO of Applications, says Chronicle Bio is building an AI data platform that matches drugs to the right patients based on their observed biology across chronic illnesses.

Simo's post also argues that clinical trials and patient data will become the bottleneck as drug discovery gets cheaper. The report does not describe the platform's launch status, partners, or results.